Spring Bank Pharmaceuticals (Wed, Feb 03, 2021)


Buy candidate since Feb 03, 2021

StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania



Frend:	Buy
/IV Long:	Buy
//V Short:	Buy
Pivot:	Buy
/olume:	Buy
MACD:	Buy

T



Tech commentaries:

The Spring Bank Pharmaceuticals stock price gained 19.21% on the last trading day (Wednesday, 3rd Feb 2021), rising from \$9.06 to \$10.80. It has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 33.36% from a day low at \$9.07 to a day high of \$12.10. The price has risen in 6 of the last 10 days and is up by 9.64% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 236 thousand more shares were traded than the day before. In total, 290 thousand shares were bought and sold for approximately \$3.13 million.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise **118.52%** during the next 3 months and, with a 90% probability hold a price between **\$19.15** and **\$35.12** at the end of this 3-month period.

Mostly positive signals in the chart today. The **Spring Bank Pharmaceuticals** stock holds buy signals from both short and longterm Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at **\$8.96** and **\$9.28**. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on **Thursday**, **January 28**, **2021**, and so far it has risen 31.87%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

On the downside, the stock finds support just below today's level from accumulated volume at **\$10.07** and **\$9.69**. There is no resistance from accumulated volume above today's level and given the right condition the stock may perform very well during the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved **\$3.03** between high and low, or **33.36%**. For the last week, the stock has had daily average volatility of **13.08%**.

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for **Spring Bank Pharmaceuticals** stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Buy candidate.

Risk: Medium

Evaluation: Buy Candidate

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.